PCSK9 and hyperlipidemia: Combination therapies integrating lipid-lowering agents like statins or PCSK9 inhibitors with anti-inflammatory drugs may offer a dual-action approach to cardiovascular risk reduction, addressing both hyperlipidemia and chronic vascular inflammation.